This book gives an expert view of how the project management approach can be taken forward by the pharmaceutical industry over the next decade. The book integrates portfolio, program, and project management processes as fundamentals for effective and efficient drug product development. This discussion has already begun at conferences, including the Drug Information Association conference on project management held in Philadelphia in February 2005, for which book editor Harpum was a co-chairperson.
This book gives an expert view of how the project management approach can be taken forward by the pharmaceutical industry over the next decade. The book integrates portfolio, program, and project management processes as fundamentals for effective and efficient drug product development. This discussion has already begun at conferences, including the Drug Information Association conference on project management held in Philadelphia in February 2005, for which book editor Harpum was a co-chairperson.Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
PETE HARPUM is a Director of Harpum Consulting and has been consulting on Portfolio, Program, and Project Management (P3M) for some ten years. He chairs and contributes to many conferences and symposiums on P3M. Mr. Harpum's other activities include postgraduate lecturing and research on P 3M for three world-class universities, and supporting the Association for Project Management, Project Management Institute, and the Drug Information Association in various ways.
Inhaltsangabe
Preface ix Acknowledgments xi About the Authors xiii Part One The Life Science Industry Context for Portfolio, Program, and Project Management 1. A Review of Project Management in Life Science Industry Sectors 3 Thomas R. Dunson 2. The Impact of Organizational Size on Drug Project Management 21 Eric Morfin 3. Drug Development in Biotechnology and How We Can Do It Better 33 Susan Linna Part Two The Portfolio, Program, and Project Management Approaches and Processes 4. An Overview of the Organization and Processes of Portfolio, Program, and Project Management 53 Pete Harpum 5. Portfolio Management in the Pharmaceutical Industry: Balancing Corporate Need with the Reality of Delivering Products to the Market 59 John Bennett 6. Program Management in Drug Development 85 Pauline Stewart-Long 7. Project Control 101 Martin Powell 8. Managing Uncertainty in Drug Projects 135 Pete Harpum and Thomas R. Dunson 9. Managing Drug Safety Risk 155 Thomas R. Dunson and Eric Morfin 10. Developing Program Strategy 175 Pete Harpum 11. Developing Products with "Added Value" 197 Trevor J. Brown and Stephen Allport Part Three Integrating the Processes 12. Integrated Business Processes to Support Cross-Functional Drug Development 227 Martin D. Hynes III 13. Integrated Drug Development: From Cradle to Grave and from Lab to Market 239 Stephen Allport and Terry Cooke-Davies 14. The Development of P3M Capability in Drug Development Organizations 259 John Arrowsmith, Patrick Grogan, and Bob Moore 15. Implementing Portfolio, Program, and Project Management Best Practices in Drug Development Organizations 287 Pete Harpum, Ashley Jamieson, and Inge Fisher Bibliography 311 Index 313
Preface ix Acknowledgments xi About the Authors xiii Part One The Life Science Industry Context for Portfolio, Program, and Project Management 1. A Review of Project Management in Life Science Industry Sectors 3 Thomas R. Dunson 2. The Impact of Organizational Size on Drug Project Management 21 Eric Morfin 3. Drug Development in Biotechnology and How We Can Do It Better 33 Susan Linna Part Two The Portfolio, Program, and Project Management Approaches and Processes 4. An Overview of the Organization and Processes of Portfolio, Program, and Project Management 53 Pete Harpum 5. Portfolio Management in the Pharmaceutical Industry: Balancing Corporate Need with the Reality of Delivering Products to the Market 59 John Bennett 6. Program Management in Drug Development 85 Pauline Stewart-Long 7. Project Control 101 Martin Powell 8. Managing Uncertainty in Drug Projects 135 Pete Harpum and Thomas R. Dunson 9. Managing Drug Safety Risk 155 Thomas R. Dunson and Eric Morfin 10. Developing Program Strategy 175 Pete Harpum 11. Developing Products with "Added Value" 197 Trevor J. Brown and Stephen Allport Part Three Integrating the Processes 12. Integrated Business Processes to Support Cross-Functional Drug Development 227 Martin D. Hynes III 13. Integrated Drug Development: From Cradle to Grave and from Lab to Market 239 Stephen Allport and Terry Cooke-Davies 14. The Development of P3M Capability in Drug Development Organizations 259 John Arrowsmith, Patrick Grogan, and Bob Moore 15. Implementing Portfolio, Program, and Project Management Best Practices in Drug Development Organizations 287 Pete Harpum, Ashley Jamieson, and Inge Fisher Bibliography 311 Index 313
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
